Objective: To investigate quantitatively the risk factors of hyperkalaemia or increased blood potassium associated with ACE-inhibitor therapy Design: Nested case-control study Methods: We used the antihypertensive drug database（72,379 subjects）developed by the RAD-AR Council, Japan and the Institute of Statistical Mathematics based on the post-marketing surveillance（PMS） data of pharmaceutical companies. Of 37,372 subjects taking ACE-inhibitors, the case group was composed of 64 patients who experienced hyperkalaemia or blood potassium increase while taking ACE-inhibitors, and the control group was composed of 1,280 patients（20 patients per case）randomly selected from patients who did not experience hyperkalaemia or blood potassium increase while taking ACE-inhibitors. The relevant factors that can be extracted from the database were the followings: age, WHO classification of hypertension, complications, antihypertensive drugs used before the PMS survey, and concomitant drugs. Results: Among the subjects taking antihypertensive agents, 65 patients experienced hyperkalaemia or increased blood potassium, 64（98.5％）of whom were taking ACE-inhibitors. The factors that were significantly different between two groups（p＜0.05）by univariate analysis were WHO classification of ／ hypertension（p＝0.005), complications of nephritis／nephrosis（p＜0.001), other disorder of urinary system（p＜0.001), unclear symptom or diagnosis（p＝0.005), taking diuretics as antihypertensive drugs before study（p＝0.032), and concomitant treatment with diuretics（p＝0.004), vasodilators（p＜0.001), and antigout agents（p＝0.001). Conditional multivariate logistic analysis of these factors yielded adjusted ／ odds ratio of 21.31 for complications of nephritis／nephrosis（p＜0.001), 6.83 for other disorder of urinary system（p＜0.001), and 2.30 for concomitant therapy with diuretics（p＝0.049).

